STOCK TITAN

Miromatrix Medical Inc. - MIRO STOCK NEWS

Welcome to our dedicated page for Miromatrix Medical news (Ticker: MIRO), a resource for investors and traders seeking the latest updates and insights on Miromatrix Medical stock.

Miromatrix Medical Inc. (symbol: MIRO) is an innovative life sciences company focused on developing bioengineered organs for transplantation. The company leverages its proprietary technology to decellularize organs and tissues from both animal and human sources, creating a platform for producing fully transplantable human organs. This cutting-edge technology aims to address the critical shortage of donor organs, potentially saving and improving countless lives.

Miromatrix has garnered significant recognition for its pioneering work. The company's CEO, Dr. Jeff Ross, recently presented their advancements in kidney bioengineering at the American Transplant Congress (ATC), where they received the prestigious Best in Congress acknowledgment. Additionally, Miromatrix's Medical Director, Dr. Jack Lake, was honored with the American Society of Transplantation's 2023 Lifetime Achievement Award, the Society's highest honor, for his outstanding contributions to the field of transplantation.

The company's current focus is on the development of human livers and kidneys, utilizing its perfusion technology platform. This platform is designed to efficiently scale the bioengineering process, making it feasible to produce a larger number of transplantable organs. Miromatrix is actively involved in various research initiatives and collaborates with leading scientists such as David Lo to advance their technology further.

Financially, Miromatrix recently reported their second-quarter 2023 results, showcasing their progress and strategic direction. They continue to engage with investors and the media through scheduled presentations at significant events such as the ARM Tissue and Engineering and Therapeutics Workshop and the H.C. Wainwright Annual Global Investment Conference.

For the latest updates and detailed information on Miromatrix Medical Inc., including their recent achievements and ongoing projects, visit their official website at miromatrix.com.

Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) successfully completes the tender offer to acquire Miromatrix Medical Inc. (Nasdaq: MIRO) for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to mirokidney™ by December 31, 2025. 22,876,102 shares of Miromatrix common stock were validly tendered, representing approximately 83% of the issued and outstanding shares. Merger Sub merged with and into Miromatrix, making it a wholly owned subsidiary of United Therapeutics. Shares of Miromatrix common stock ceased trading on Nasdaq, and United Therapeutics intends to cause such shares to be delisted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) and Miromatrix Medical Inc. (Nasdaq: MIRO) announced the results of the tender offer by Merger Sub, a United Therapeutics subsidiary, to acquire all outstanding shares of Miromatrix for $3.25 per share in cash at closing and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s mirokidney™ product by December 31, 2025. The tender offer expired with shares representing more than a majority of the issued and outstanding Miromatrix common stock validly tendered and received. The merger is expected to be completed on December 13, 2023, with Miromatrix becoming a wholly owned subsidiary of United Therapeutics and its shares delisted from Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Miromatrix Medical Inc. (Nasdaq: MIRO) reported third quarter 2023 financial results and announced a definitive merger agreement with United Therapeutics Corporation. The company's unrestricted cash and investments totaled $16.1 million, with an operating loss of $6.6 million for the third quarter. Miromatrix has agreed to be acquired by United Therapeutics for $3.25 per share in cash at closing, with an additional $1.75 per share upon the achievement of a clinical development milestone related to their mirokidney™ product by December 31, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
United Therapeutics Corporation (Nasdaq: UTHR) has announced its definitive agreement to acquire Miromatrix Medical Inc. (Nasdaq: MIRO), a life sciences company focused on bioengineered organs. The acquisition will expand United Therapeutics' organ manufacturing programs and address the shortage of transplantable organs. The purchase price is $3.25 per share in cash at closing, with an additional $1.75 per share upon achieving a clinical development milestone. The transaction is expected to close in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Miromatrix Medical Inc. to present at ISODP Organ Donation Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
conferences
-
Rhea-AI Summary
Miromatrix Medical Inc. CEO to present at 2023 Cell & Gene Meeting on the Mesa
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences
Rhea-AI Summary
Miromatrix Medical Inc. to present at H.C. Wainwright Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.65%
Tags
none
-
Rhea-AI Summary
Miromatrix Medical Inc. to present at ARM Tissue Engineering and Therapeutics Workshop on September 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.27%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences earnings

FAQ

What is the market cap of Miromatrix Medical (MIRO)?

The market cap of Miromatrix Medical (MIRO) is approximately 93.0M.

What does Miromatrix Medical Inc. specialize in?

Miromatrix Medical Inc. specializes in developing bioengineered organs for transplantation using a proprietary decellularization technology.

What recent recognition has Miromatrix received?

Miromatrix received the Best in Congress acknowledgment at the American Transplant Congress and their Medical Director, Dr. Jack Lake, received the 2023 Lifetime Achievement Award from the American Society of Transplantation.

What are Miromatrix's primary focus areas?

Miromatrix is currently focusing on the development of bioengineered human livers and kidneys.

What technology does Miromatrix use for bioengineering organs?

Miromatrix uses a proprietary perfusion technology platform to decellularize organs and tissues, facilitating the creation of fully transplantable human organs.

How is Miromatrix addressing the shortage of donor organs?

Miromatrix's technology aims to produce fully biological transplantable organs, thus potentially increasing the supply of available organs for transplantation.

Who are some key figures in Miromatrix?

Key figures include Dr. Jeff Ross, CEO, and Dr. Jack Lake, Medical Director.

What events has Miromatrix recently participated in?

Miromatrix has participated in the American Transplant Congress (ATC), the ARM Tissue and Engineering and Therapeutics Workshop, and the H.C. Wainwright Annual Global Investment Conference.

Where can I find more information about Miromatrix?

More information can be found on their official website at miromatrix.com.

What recent financial results has Miromatrix reported?

Miromatrix recently reported their second-quarter 2023 financial results, detailing their progress and strategic direction.

Who can I contact for investor relations at Miromatrix?

For investor relations, you can contact Greg Chodaczek at 347-620-7010 or via email at ir@miromatrix.com.

Miromatrix Medical Inc.

Nasdaq:MIRO

MIRO Rankings

MIRO Stock Data

92.95M
20.65M
24.68%
22.04%
0.04%
Biotechnology
Healthcare
Link
United States
Eden Prairie